118 related articles for article (PubMed ID: 10517447)
21. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
[TBL] [Abstract][Full Text] [Related]
22. [Computed tomography, primary laparotomy and second look surgery in ovarian carcinoma].
Triller J; Goldhirsch A
Rofo; 1984 Mar; 140(3):294-303. PubMed ID: 6423485
[TBL] [Abstract][Full Text] [Related]
23. From the archives of the AFIP. Ovarian epithelial neoplasms: radiologic-pathologic correlation.
Wagner BJ; Buck JL; Seidman JD; McCabe KM
Radiographics; 1994 Nov; 14(6):1351-74; quiz 1375-6. PubMed ID: 7855346
[TBL] [Abstract][Full Text] [Related]
24. Human ovarian tumors express gamma-glutamyl transpeptidase.
Hanigan MH; Frierson HF; Brown JE; Lovell MA; Taylor PT
Cancer Res; 1994 Jan; 54(1):286-90. PubMed ID: 7903206
[TBL] [Abstract][Full Text] [Related]
25. Correlation of computed tomography with second-look laparotomy in ovarian carcinoma.
Sandhu M; Kumar L; Kumar S; Kriplani A; Bhatla N; Kinra G
Natl Med J India; 1996; 9(1):13-6. PubMed ID: 8713518
[TBL] [Abstract][Full Text] [Related]
26. [Value of radioimmunoscintigraphy compared to computed tomography in the diagnosis and follow-up of primary ovarian carcinoma].
Barzen G; Cordes M; Langer M; Friedman W; Mayr AC; Felix R
Rofo; 1990 Jul; 153(1):85-91. PubMed ID: 2166319
[TBL] [Abstract][Full Text] [Related]
27. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors.
Farré X; Guillén-Gómez E; Sánchez L; Hardisson D; Plaza Y; Lloberas J; Casado FJ; Palacios J; Pastor-Anglada M
Int J Cancer; 2004 Dec; 112(6):959-66. PubMed ID: 15386342
[TBL] [Abstract][Full Text] [Related]
28. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
[TBL] [Abstract][Full Text] [Related]
29. [Expression of folate receptor alpha in ovarian epithelial tumors].
Shen DH; Xie JL; Zhang YL; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165
[TBL] [Abstract][Full Text] [Related]
30. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report.
Method MW; Serafini AN; Averette HE; Rodriguez M; Penalver MA; Sevin BU
Cancer; 1996 Jun; 77(11):2286-93. PubMed ID: 8635097
[TBL] [Abstract][Full Text] [Related]
31. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
Demeter A; Várkonyi T; Csapó Z; Szánthó A; Oláh J; Papp Z
Magy Onkol; 2004; 48(3):259-65. PubMed ID: 15520877
[TBL] [Abstract][Full Text] [Related]
32. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
Shi W; Zhang YJ; Jiang CY
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
[TBL] [Abstract][Full Text] [Related]
33. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer.
Mutch DG; Prat J
Gynecol Oncol; 2014 Jun; 133(3):401-4. PubMed ID: 24878391
[No Abstract] [Full Text] [Related]
34. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
35. The histologic subtype of ovarian tumors affects the detection rate by pelvic washings.
Fadare O; Mariappan MR; Wang S; Hileeto D; McAlpine J; Rimm DL
Cancer; 2004 Jun; 102(3):150-6. PubMed ID: 15211473
[TBL] [Abstract][Full Text] [Related]
36. Differences in tumor type in low-stage versus high-stage ovarian carcinomas.
Köbel M; Kalloger SE; Huntsman DG; Santos JL; Swenerton KD; Seidman JD; Gilks CB;
Int J Gynecol Pathol; 2010 May; 29(3):203-11. PubMed ID: 20407318
[TBL] [Abstract][Full Text] [Related]
37. Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission. Correlation with surgical-pathologic findings.
Clarke-Pearson DL; Bandy LC; Dudzinski M; Heaston D; Creasman WT
JAMA; 1986 Feb; 255(5):627-30. PubMed ID: 3944963
[TBL] [Abstract][Full Text] [Related]
38. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
39. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
[TBL] [Abstract][Full Text] [Related]
40. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma.
Welt CK; Lambert-Messerlian G; Zheng W; Crowley WF; Schneyer AL
J Clin Endocrinol Metab; 1997 Nov; 82(11):3720-7. PubMed ID: 9360531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
